TIME ZONES
NPGS 2022 Agenda
NOTE: This agenda is not final, additional
items may be added as they are confirmed.
Please visit the video archive for informative sessions
covering the basics of neuroblastoma, current treatments, and more.
Friday 11 November
Welcome
14:00 London Time
Dr. Daniel Morgenstern will welcome you to the event, review the event platform, where to find resources, and kick off the event with the first session.
TREATING HIGH-RISK NEUROBLASTOMA IN 2022 - Where Are We Now?
14:05 -14:30 London Time
Dr. Daniel Morgenstern will give participants an overview of the current landscape for treating high-risk neuroblastoma.
THE CHALLENGE OF CURING HIGH-RISK NEUROBLASTOMA
14:30 -16:20 London Time
- Finding the right treatment, for the right patient with Dr. Jan Molenaar
- Chemoimmunotherapy, a major breakthrough? with Dr. Rajen Mody
- Is an extended induction right for some patients? with Dr. Sara Federico
- High-Risk and Relapsed Neuroblastoma: Toward More Cures and Better Outcomes, 2022 ASCO publication, with Dr. Steven DuBois
Followed by a 45 minute Q&A.
Moderated by Donna Ludwinski.
CAR-T CELL THERAPIES - Where Are We Now?
16:35 -18:25 London Time
- Optimising CAR-T cells against neuroblastoma with Dr. John Anderson
- GD2 specific CAR and interleukin-15 expressing autologous NKT cells with Dr. Andres Heczey
- PHOX2B peptide-specific CAR-T cells with Dr. Mark Yarmarkovich
- GPC2 CAR for neuroblastoma with Dr. Rosa Nguyen
Followed by a 45 minute Q&A.
Moderated by Antonia Palmer
SPECIAL INTEREST TALK - Anti-GD2
18:40 -19:30 London Time
Gregory Sizikov will host this special interest talk with Dr. Robbie Majzner and Dr Juliet Gray who will cover Anti-GD2, what we know, what do we still need to understand, and what about children without GD2 expression.
SPECIAL INTEREST TALK - TBA
18:40 -19:30 London Time
Wrap Up
19:30 London Time
Dr. Daniel Morgenstern provides a summary of the day's presentations and the event closes with a moving tribute to neuroblastoma children from around the world.